BioRestorative Therapies, Inc.
BRTX
$1.71
$0.021.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 175.03% | 189.55% | 35.49% | 10.66% | 21.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 175.03% | 189.55% | 35.49% | 10.66% | 21.70% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 155.83% | 170.58% | 30.43% | 10.66% | 21.70% |
| SG&A Expenses | -41.76% | -41.81% | -39.25% | -37.98% | -27.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.19% | -25.87% | -28.60% | -30.93% | -19.52% |
| Operating Income | 24.08% | 27.55% | 29.05% | 31.21% | 19.78% |
| Income Before Tax | 13.81% | -34.20% | 77.20% | 64.90% | 21.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.81% | -34.20% | 77.20% | 64.90% | 21.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.81% | -34.20% | 77.20% | 64.90% | 21.21% |
| EBIT | 24.08% | 27.55% | 29.05% | 31.21% | 19.78% |
| EBITDA | 24.50% | 27.97% | 29.46% | 31.60% | 20.15% |
| EPS Basic | 59.07% | 30.80% | 93.73% | 70.50% | 22.60% |
| Normalized Basic EPS | 66.48% | 30.80% | 93.73% | 70.50% | 24.06% |
| EPS Diluted | 66.59% | 47.08% | 78.89% | 55.10% | 4.84% |
| Normalized Diluted EPS | 72.76% | 47.26% | 78.89% | 55.02% | 6.55% |
| Average Basic Shares Outstanding | 84.08% | 74.29% | 61.33% | 35.17% | 16.56% |
| Average Diluted Shares Outstanding | 26.10% | 17.00% | 113.34% | 88.06% | 70.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |